Search

Search Constraints

You searched for: Author/Creator Dimopoulos, Meletios A.

Search Results

1. A matching-adjusted indirect treatment comparison (MAIC) of daratumumab–bortezomib–melphalan–prednisone (D-VMP) versus lenalidomide–dexamethasone continuous (Rd continuous), lenalidomide–dexamethasone 18 months (Rd 18), and melphalan–prednisone–thalidomide (MPT). Issue 3 (23rd February 2020)

2. A phase 2, randomized, double‐blind, placebo‐controlled study of siltuximab (anti‐IL‐6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. Issue 1 (January 2015)

3. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. (7th January 2013)

6. Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low‐dose dexamethasone: A pooled analysis. (14th June 2017)

7. Age‐dependent and gender‐dependent antibody responses against SARS‐CoV‐2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine. Issue 7 (24th April 2021)

8. Alcohol consumption and risk of hematological malignancies: A meta‐analysis of prospective studies. Issue 3 (30th March 2018)

10. All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. (January 2019)